Intensive Blood Pressure Treatment Goals: Evidence for Cardiovascular Protection From Observational Studies and Clinical Trials

Epidemiologic studies have consistently identified a strong, progressive relationship between blood pressure (BP) and cardiovascular disease (CVD) events, in a range of systolic BP (SBP) from as low as 90 mm Hg to as high as 180 mm Hg. Clinical trials have demonstrated greater prevention of CVD with...

Full description

Saved in:
Bibliographic Details
Published in:American journal of hypertension 2022-11, Vol.35 (11), p.905-914
Main Authors: Whelton, Paul K, Bundy, Joshua D, Carey, Robert M
Format: Article
Language:English
Subjects:
Antihypertensive Agents - therapeutic use
Blood Pressure
Cardiovascular Diseases - drug therapy
Humans
Hypertension
Randomized Controlled Trials as Topic
Review
Risk Factors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Epidemiologic studies have consistently identified a strong, progressive relationship between blood pressure (BP) and cardiovascular disease (CVD) events, in a range of systolic BP (SBP) from as low as 90 mm Hg to as high as 180 mm Hg. Clinical trials have demonstrated greater prevention of CVD with more compared with less intensive antihypertensive drug treatment. Meta-analyses of randomized controlled trials provide strong evidence for more intensive antihypertensive drug therapy down to an SBP of 130 mm Hg, and to an SBP 120-124 mm Hg in the meta-analysis with the greatest statistical power. In the Systolic Blood Pressure Intervention Trial (SPRINT) randomization to an SBP treatment goal of
ISSN:0895-7061
1941-7225
DOI:10.1093/ajh/hpac045